Modality
Peptide
MOA
MDM2i
Target
SOS1
Pathway
Epigenetic
AML
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
Aug 2020
→ Apr 2031
Phase 3Current
NCT07722525
2,824 pts·AML
2022-10→2028-10·Not yet recruiting
NCT04895370
258 pts·AML
2020-08→TBD·Recruiting
NCT04824895
807 pts·AML
2023-11→2031-04·Active
+1 more trial
6,366 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-09-045mo awayPh3 Readout· AML
2028-10-202.6y awayPh3 Readout· AML
2031-04-035.0y awayPh3 Readout· AML
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Recruit…
P3
Not yet…
P3
Active
P3
Not yet…
Catalysts
Ph3 Readout
2026-09-04 · 5mo away
AML
Ph3 Readout
2028-10-20 · 2.6y away
AML
Ph3 Readout
2031-04-03 · 5.0y away
AML
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07722525 | Phase 3 | AML | Not yet recr... | 2824 | PFS |
| NCT04895370 | Phase 3 | AML | Recruiting | 258 | UPCR |
| NCT04824895 | Phase 3 | AML | Active | 807 | UPDRS |
| NCT06391350 | Phase 3 | AML | Not yet recr... | 2477 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 |